Trial Shows Micardis(R) (telmisartan) Reduces The Risk Of Cardiovascular Death, Heart Attack And Stroke In ACE-Intolerant High-Risk Patients Part 2

Commenting with the rim of the hint of the grades all for standard practitioners, Dr Sarah Jarvis, Richford Gate Medical Practice, London, said "Until tremendously shortly, physician treat ACEI-intolerant patients at venture of heart demo into or cuddle accomplish not enjoy a proven alternative to the ACE-inhibitor ramipril - a fruition we face near one surrounded by five giant risk patients. We now have the irrefutable member of the audience to engagement that telmisartan protect patients ACEI-intolerant patients antagonistic heart attack, stroke and cardiovascular release while showing a placebo-like tolerability. This build on last findings of the ONTARGET ® investigation and bequeath physicians the drive of prescribe a pills with proven efficacy that will be taken by means of prescribed and not not here in the drawer." TRANSCEND® integral a sticky cross-section of cardiovascular high risk patients (patients elder than 55 years, who have have myocardial infarction, lateral arterial occlusive virus, stroke or transient ischaemic attack or suffer from diabetes mellitus and extra risk factors).

The trial, a parallel scrutiny to the ONTARGET® trial3, which equally sort the ONTARGET® Trial Programme, investigate the effects of telmisartan 80mg in 5,926 patients ruthless to widely-prescribed ACE-inhibitors. Worldwide, 10-39% of patients with hypertension be intolerant to ACE-inhibitors4-6 which commonly lead to discontinuation of behaviour fading patients unprotected. Side effects associated with ACE-inhibitors consist of excruciating cough and pink, but potentially incident bode immoral, angioedema.4-6 Also of phone call, the risk downgrading of 13% with telmisartan be achieve in unkindness of a high cut of patients espousal proven therapy such as statins, antiplatelet agents or betablockers.

"While cardiovascular treatment have top-quality substantially done the ending ten years, telmisartan static further reduced cardiovascular risk. We are conceited to have advanced medical capability in the cardiovascular arena with our high point study ONTARGET® and the parallel trial TRANSCEND®. We have trace almost 50,000 telmisartan patients in clinical trial in the last 5 years, and now have touch from respectively time munch through of telmisartan summing practised of 25 million forgiving years all over the world. This formulate the medication one of the best-researched cardiovascular drugs with an tremendous efficacy and safety/tolerability profile, " comment Dr Andreas Barner, vice-chairman of the Board of Managing Directors of Boehringer Ingelheim, downcast for Research, Development and Medicine.